DEKARON North America/Europe Service Finally Managed by Developer
The long-awaited new class, 'ALOKES,' has finally arrived.
DEKARON is a 3D fantasy MMORPG characterized by its dark and intense atmosphere, featuring thrilling combat mechanics and extreme action. Players undertake missions through in-game heroes to prevent the resurrection of the sealed 'Karon.'
UBIFUN, the company that develops and services DEKARON, has been directly involved in the game's development for a long time. From the beginning of the service, UBIFUN has emphasized the importance of "communication" with players. To uphold this commitment, the company engages in real-time conversations with users through Discord and other channels, receiving significant positive feedback from the community.
In fact, since the service transfer on
Character information from the existing VFUN DEKARON can be transferred to UBIFUN's DEKARON service website at https://dekaron.ubifungames.com/ until
- Experience the Thrill of Dynamic Combat
- Engage in hack-and-slash style battles with vibrant skill effects.
- Experience 15 unique character classes, each with different playstyles.
- Enjoy a variety of PvP content such as
DK Square , Zuto's Battlefield, Battle Royale, and Siege Warfare.
About UBIFUN
UBIFUN Inc., the long-term developer and service provider of DEKARON, is responsible for the game's development across various countries and regions, including
UBIFUNGAMES DEKARON: https://dekaron.UBIFUNgames.com/
Discord: https://discord.gg/VVpEXwE6
Facebook: https://www.facebook.com/Dekaron.UBIFUN/
View original content to download multimedia:https://www.prnewswire.com/news-releases/dekaron-north-americaeurope-service-finally-managed-by-developer-302176444.html
SOURCE UBIFUN Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Max Stock updates proposed Compensation Policy and CEO terms ahead of September 15 EGM
- TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis
- Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share